Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 10/20 | 0.38 |
| ▸ | JAK1 | P23458 | 10/20 | 0.38 |
| ▸ | TYK2 | P29597 | 10/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18284044 | 0.99 | PIK3CD (0.42) | PIK3CDIRAK4IRAK1JAK2JAK1 | |
| SCHEMBL28857028 | 0.82 | RET (0.47) | PIK3CDIRAK4JAK3 | |
| SCHEMBL18284053 | 0.81 | JAK3 (0.49) | PIK3CDIRAK4JAK2JAK1TYK2 | |
| SCHEMBL18283852 | 0.79 | JAK3 (0.46) | JAK3 | |
| SCHEMBL18296104 | 0.77 | PIK3CD (0.50) | PIK3CDIRAK4JAK2JAK1TYK2 | |
| SCHEMBL23080834 | 0.72 | JAK3 (0.48) | PIK3CDJAK2JAK1TYK2JAK3 | |
| SCHEMBL28856908 | 0.71 | JAK3 (0.47) | PIK3CDJAK3 | |
| SCHEMBL28856906 | 0.71 | JAK3 (0.47) | PIK3CDJAK3 | |
| SCHEMBL22346927 | 0.70 | JAK3 (0.52) | PIK3CDJAK3 | |
| SCHEMBL22346924 | 0.70 | JAK3 (0.52) | PIK3CDJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2021-03-11 | — | — | US | disclosed |
| EP-3310776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Pharmacyclics LLC (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016196776-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC. (US) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070748-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | PIK3CD 138/4885IRAK4 286/4885IRAK1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.